“The linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine”
Oncologica addresses this new era of precision medicine by exploiting state of the art molecular profiling enabling a patient’s tumour to be matched directly with the most appropriate molecular targeted therapy.
Oncologica’s semiconductor profiling technology reduces the number of tests required for comprehensive tumour analysis, delivers faster results and at a much lower cost.
Our scientists and clinicians utilise state-of-the-art next generation semiconductor sequencing technology (NGS) to rapidly detect actionable mutations in patients’ tumour samples to precisely match these alterations with new generation targeted therapies.
The Oncofocus Assay, a targeted sequencing platform, is designed to detect actionable mutations in cancer genes targeted by on-market oncology drugs or treatments in clinical trials. Intelligent design is driven by Oncologica’s bioinformatics platforms linked to the world’s largest curated compendium of cancer genomic information, including content aligned to approved therapies, current practice guidelines and open clinical trials.
Our targeted next generation sequencing assay enables simultaneous detection of thousands of genetic variants across 52 genes relevant to solid tumours. Targeted actionable hotspots include SNVs, indels, CNVs and gene fusions.
Analysis of the output from the Oncofocus assay is performed using Oncofocus Reporter, an analytical system used to identify and prioritise potential treatment strategies. This analytical platform enables Oncofocus detected variants to be linked to over 270 targeted therapies
NGS
C
G
T
A
Oncologica carries out DNA sequencing of patients’ tumour samples using semiconductor chip technology directly translating chemically encoded information (A, C, G, T) into digital information.
Semiconductor sequencing has major advantages over other sequencing technologies because it can be used to sequence low DNA/RNA input FFPE biopsy samples with high throughput and at a reduced cost.
• Nucleotides flow sequentially over an Ion semiconductor chip
• One sensor per well per sequencing reaction
• Direct detection of natural DNA extension
• Millions of sequencing reactions per chip
• Fast cycle time, real time detection
NEXT GENERATION SEQUENCING (NGS)TECHNOLOGY
Ion semiconductor chip
dNTP
H+
sensing layersensor plate
silicon substratebulk drain source
DNA Ions Sequence
To columnreceiver
Rothberg J.M. et al Nature doi:10/1038/nature10242
THE FIRST LABORATORY IN EUROPE TO OFFER ONCOFOCUS The world’s most comprehensive precision oncology test
4 5
Delivering New Generation MolecularProfiling for cancer targeted therapies
to optimize treatment efficacyComprehensive analysis of major cancer driver genes in one single workflow dramatically reducing the cost of molecular profiling and accelerating reporting times
Reduced number of tests that cancer patients require
NGS semiconductor platform uses low DNA/RNA input (10ng) from FFPE samples enabling detection of actionable variants in fine needle biopsies and core needle aspirates
Generates a comprehensive picture of actionable mutations providing the clinician with a detailed molecular blueprint for optimal therapy choices and improved patient outcomes
Prevent the unwarranted prescribing of expensive targeted therapies to patients unlikely to benefit from such treatments
Identification of specific mutations known to be associated with response or resistance to targeted therapies
Identification of new driver mutations following relapse allowing a switch to additional more appropriate targeted therapies
Identification of driver mutations and linked therapies in rare tumour types for which treatment protocols are limited
Molecular profiling conducted on routine diagnostic histological samples (formalin fixed paraffin embedded specimens) and liquid biopsies including circulating tumour DNA and circulating tumour cells (ctDNA and CTCs)
6 7
TARGETED NGS FOR ALL SOLID TUMOUR TYPES
TARGETED TREATMENTS
ALK FUSION
BRAF MUTATION
COBIMETINIB + RG-7446
CABOZANTINIB
CETUXIMAB
PANITUMUMAB
VORINOSTAT
DASATINIB
AFATINIB
CERITINIB + CHEMOTHERAPY
NERATINIB
DABRAFENIB
EVEROLIMUS
KIT FUSION
EGFR MUTATION
ERBB2 AMPLIFICATION
PDGFRA AMPLIFICATION
CDKN2A MUTATION
SMO MUTATION
NTRK2 FUSION
RET MUTATION
KIT MUTATION
FGFR4 MUTATIONERBB2 AMPLIFICATION
PIK3CA AMPLIFICATION
CLR-457
IMATINIB MESYLATE
Bladder
Breast
Colorectal
Endometrial
Oesophagus
Gastric
Mesothelioma Osteosarcoma
Ovarian Pancreatic
GIST
Glioblastoma
Head and Neck
Kidney
Liver
Testicular
Thyroid
Prostate
Skin
Small Cell Lung Cancer
Soft Tissue SarcomaNon Small Cell Lung Cancer
MELANOMA
AFATINIB
TRASTUZUMAB
VEMURAFENIB
CRIZOTINIB
NTRK3 MUTATION
ROS1 FUSION
FGFR3 FUSION
ERBB2 AMPLIFICATION
EGFR MUTATION
BRAF MUTATION
PDGFRA MUTATION
NTRK2 MUTATION
The fully integrated Oncofocus Assay and linked Oncofocus Reporter Database provides unparalleled information regarding an individual’s tumour that can be exploited to optimise treatment selection using the new generation of molecular targeted agents.
TUMOUR TYPE GENETIC VARIANTS
35 genes and hundreds of variants tested in this tumour type
TARGETED THERAPIES
Over 110 potential treatments in this tumour type
8 9
TARGETED NGS FOR ALL SOLID TUMOUR TYPES
FGFR2 AMPLIFICATION
AXL FUSION
MET FUSION
TSC2 MUTATION
SMO MUTATION
AXL FUSION
Bladder
Breast
Colorectal
Endometrial
Oesophagus
Gastric
Mesothelioma Osteosarcoma
Ovarian Pancreatic
GIST
Glioblastoma
Head and Neck
Kidney
Liver
Testicular
Thyroid
Prostate
Skin
Small Cell Lung Cancer
Soft Tissue SarcomaNon Small Cell Lung Cancer
EGFR FUSION
AKL FUSION
PDGFRA MUTATION
CDK4 MUTATION
HRAS MUTATION
CRIZOTINIB + DASATINIB
IPILIMUMAB
VEMURAFENIB
IMATINIB MESYLATE
VORINOSTAT
CABOZANTINIB
CLR-457
JNJ-42756493
CETUXIMAB
DABRAFENIB
ERLOTINIB
NERATINIB
ABL1 ABERRATION
PTCH1 MUTATION
RET MUTATION
BRAF MUTATIONERBB2 AMPLIFICATION
EGFR MUTATION
AFATINIB
DABRAFENIB + TRAMETINIB
MGCD-265
JNJ-42756493
CERITINIB
RIBOCICLIB
NTRK3 MUTATION
CDK4 MUTATION
EGFR AMPLIFICATIONFGFR2 FUSION
PROSTATE
TUMOUR TYPE GENETIC VARIANTS
35 genes and hundreds of variants tested in this tumour type
TARGETED THERAPIES
Over 90 potential treatments in this tumour type
NTRK2 FUSION
MAP2K1 MUTATION
ALK FUSION
TARGETED TREATMENTSThe fully integrated Oncofocus Assay and linked Oncofocus Reporter Database provides unparalleled information regarding an individual’s tumour that can be exploited to optimise treatment selection using the new generation of molecular targeted agents.
10 11
TARGETED NGS FOR ALL SOLID TUMOUR TYPES
ERBB2 MUTATION
MET AMPLIFICATION
MET FUSIONTSC2 MUTATION
KRAS MUTATION
Bladder
Breast
Colorectal
Endometrial
Oesophagus
Gastric
Mesothelioma Osteosarcoma
Ovarian Pancreatic
GIST
Glioblastoma
Head and Neck
Kidney
Liver
Testicular
Thyroid
Prostate
Skin
Small Cell Lung Cancer
Soft Tissue Sarcoma
RET FUSION
MET AMPLIFICATION
KIT MUTATION
BRAF MUTATION
PDGFRA MUTATION
LUNG
HRAS MUTATION
NIVOLUMABDASATINIB
IMATINIB MESYLATE
TRASTUZUMAB + CAPECITABINE
GEFITINIBVEMURAFENIB
CLR-457
AZD-9291
AFATINIB
DABRAFENIB
PALBOCICLIB
EGFR MUTATION
PTCH1 MUTATION
RET MUTATION
ALK FUSION
KRAS G12 MUTATION CETUXIMAB*
CRIZOTINIB
CRIZOTINIB
ERLOTINIB
CABOZANTINIB
DASATINIB
ERBB2 AMPLIFICATION
EGFR MUTATION
ALK FUSION
PDGFRA MUTATION
CDK4 MUTATION
EGFR MUTATION
TUMOUR TYPE GENETIC VARIANTS
12 genes and hundreds of variants tested in this tumour type
TARGETED THERAPIES
Over 30 potential treatments in this tumour type
*contraindicate
TARGETED TREATMENTSThe fully integrated Oncofocus Assay and linked Oncofocus Reporter Database provides unparalleled information regarding an individual’s tumour that can be exploited to optimise treatment selection using the new generation of molecular targeted agents.
12 13
Life Technologies Clinical Services Lab 910 Riverside Parkway, Suite 60 | West Sacramento, CA 95605
Ph: (888) 734-8588 | Fax: (855) 896-0909 [email protected] | lifelabdx.com
Oncomine Cancer Panel Patient Test Report
SUBJECT INFORMATION
SITE INFORMATION
Pre-Screening Subject No.: ________________________ Investigator Name: __________________________________ Subject Initials: ___________ (first/middle/last)
Date of Birth: _________ (dd/mmm/yyyy)
Site ID: _______________
Date of Shipment: __________ (dd/mmm/yyyy)
Gender: ☐ M ☐ F
Phone: ________________
Fax: _____________________
SPECIMEN INFORMATION Accession No.: __________________
Date Specimen Received: ________________
Date Reported: _______________
TEST RESULTS
In this cancer type In other cancer type In this cancer type and other
cancer types Contraindicated No evidence available
Mutations
Gene Amino Acid
Change Geneotype Classification
Current FDA Information
NCCN Guideline
Number of therapies with clinical trials in this
therapies
KRAS p.Ala146Thr c.436G>A Gain of Function 2 15
KIT p.Met541Leu c.1612A>C Gain of Function 1 1
MET p.Asn375Ser c.1124A>G Gain of Function 3
TP53 p.Arg234Cys c.700C>T Loss of Function 1
TP53 p.Pro33Arg c.98C>G Loss of Function 1
Copy Number Variations
Gene Type Classification Current FDA Information
NCCN Guideline
Number of therapies with clinical trials in this therapies
PTEN Deletion Loss of Function 5
There is no current FDA information, NCCN guidelines, or open clinical trials for the following detected copy number variations: RPS6KB1 Amplification, FLT3 Amplification, ACVRL1 Amplification, PTCH1 Deletion, CDKN2A Deletion, MYC Amplification, TERT Amplification, TET2 Deletion, VHL Deletion. Other mutations, copy number variations, or fusions of that were detected but not classified by the Oncomine Knowledgebase as a genetic driver of cancer are not listed in the results section of this report. All other genes listed in the Test Description that do not appear in the results section either did not have a detected variant or the variant is not classified as a genetic driver for cancer.
Laboratory director: John E. Glassco, MD, FCAP CLIA number: 05D1067109
Life Technologies Clinical Services Lab tests are intended for clinical use. They were developed and their performance characteristics determined by the Life Technologies Clinical Services Lab, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity testing. The tests have not been cleared or approved by the United States Food and Drug Administration; however, such clearance or approval is not currently required. ©2014 Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation and/or its affiliate(s).
ONCOFOCUS PATIENT TEST REPORT
TEST RESULTS SUMMARY
Publishedtherapiessummary
Inthiscancer
type
Inothercancer
type
Inthiscancertypeand
othercancertypes
Contraindicated Noevidence
available
(IV),(III),(II/III),(II),(I/II),(I)
Clinicaltrialphase
PublishedtherapyCurrentFDAinformation
NCCNGuidelines
Openclinicaltrialsforthiscancertype*
cetuximab
panitumumab
panitumumab+chemotherapy (II)
regorafenib+FOLFIRI (II)
sorafenib+cetuximab (II)
binimetinib+panitumumab (I/II)
BVD-523 (I/II)
navitoclax+trametinib (I/II)
palbociclib (I/II)
binimetinib+BYL-719 (I)
BMS-906024 (I)
buparlisib+irinotecan (I)
cobimetinib+RG-7446 (I)
MEHD-7945A+cobimetinib (I)
PD-0325901+PF-04691502,PF-04691502+irinotecan,PD-0325901+
irinotecan
(I)
trametinib+uprosertib (I)
vorinostat+hydroxychloroquine (I)
*Mostadvancedphaseisshownandmultipleclinicaltrialsmaybeavailable.SeeOpenclinicaltrialssectioninthepagestofollow.
KRASA146mutationinColorectalCancer 1of9
Disclaimer:Thedatapresentedhereisaresultofthecurationofpublishedliterature,butmaynotbeexhaustive.
©2014ThermoFisherScientific.Allrightsreserved.
Oncomine CancerResearchPanelKnowledgebasev1.1®
PUBLISHED THERAPIES SUMMARY
Evidenceandprevalencesummarybyclass
Prevalence*
ClassEvidenceitems
Thiscancertype
KRASmutationstatus 2 35.5%
KRASmutation 15 35.5%
KRASnon-G12mutation 1 8.1%
KRASA146mutation 1 <1%
*Source:Oncomine CancerResearchPanelKnowledgebase(ThermoFisherScientific,AnnArbor,MI)
Publishedtherapiesdetail
cetuximab
cetuximab
Aclasshierarchywascreatedtosummarizegenevariantswithassociatedclinicalevidence.Evidenceitemsreferstouniquecitations
(CurrentFDAinformation,NCCNGuidelines,orclinicaltrialeligibilitycriteria).Anestimateofprevalenceofthegenevariantinthecancer
typeisprovided.
Inthiscancertype Inothercancertypes Inthiscancertypeandothercancertypes Contraindicated
NCCNGuidelines
NCCNGuidelinesinformationiscurrentasof2014-07-01.Forthemostup-to-dateinformation,gotowww.nccn.org.
Cancertype:ColorectalCancer
Class:
KRASmutation
Contraindication:
Baseduponlower-levelevidence,thereisuniformNCCNconsensus(Category2A)that
patientswithanyknownKRASorNRASmutationshouldnotbetreatedwitheither
cetuximaborpantitumumab.(COL-A4of5,MS-34)
Reference:
NCCNGuidelineVersion3.2014ColonCancer
Cancertype:ColorectalCancer
Class:
KRASmutation
Contraindication:
Baseduponlower-levelevidence,thereisuniformNCCNconsensus(Category2A)that
patientswithanyknownKRASorNRASmutationshouldnotbetreatedwitheither
cetuximaborpantitumumab.(REC-A5of6,MS-29andMS-30)
Reference:
NCCNGuidelineVersion3.2014RectalCancer
KRASA146mutationinColorectalCancer 2of9
®
Disclaimer:Thedatapresentedhereisaresultofthecurationofpublishedliterature,butmaynotbeexhaustive.
©2014ThermoFisherScientific.Allrightsreserved.
Oncomine CancerResearchPanelKnowledgebasev1.1®
PUBLISHED THERAPIES DETAIL - NCCN GUIDELINES
Openclinicaltrials(cont'd)
Clinicaltrialinformationiscurrentasof2014-07-01.Forthemostup-to-dateinformationregardingaparticulartrial,search
www.clinicaltrials.govbyNCTID.
NCT01449058:APhaseIbOpen-label,
Multi-center,DoseEscalationand
ExpansionStudyofOrallyAdministered
MEK162PlusBYL719inAdultPatients
WithSelectedAdvancedSolidTumors
Class:
KRASmutation
Populationsegment(s):
HER2negative,Highrisk,Secondlineorgreater/Refractory/Relapsed,StageII,StageIII,
StageIV,Triplereceptornegative
Phase:
I
Publishedtherapy:
binimetinib+BYL-719
Location(s):
CA,IL,MA,TX,UT
Contact:
NovartisPharmaceuticals[1-862-778-8300]
NCT01304602:APhaseITrialof
IrinotecanandBKM120inPreviously
TreatedAdvancedColorectalCancer
Class:
KRASmutation
Populationsegment(s):
Secondlineorgreater/Refractory/Relapsed,StageIII,StageIV
Phase:
I
Publishedtherapy:
buparlisib+irinotecan
Location(s):
KS
Contact:
StaceyPurinton[913-588-2545;[email protected]]
KRASA146mutationinColorectalCancer 6of9
Disclaimer:Thedatapresentedhereisaresultofthecurationofpublishedliterature,butmaynotbeexhaustive.
©2014ThermoFisherScientific.Allrightsreserved.
Oncomine CancerResearchPanelKnowledgebasev1.1®
PUBLISHED THERAPIES DETAIL - OPEN CLINICAL TRIALS
SUBJECT INFORMATION SITE INFORMATION
: ___________ ( )
Date of B irth: ___ ______ (dd/mm/yyyy)
Site ID: ____ ____ _______
Gender: M F Phone: ________________ :____ ______ ___________
SPECIMEN INFORMATION
No.: __ ________________ Date S pecimen R eceived: ______ __________ Date Reported: _______________
T
TEST RESULTS
In this cancer type In other cancer type In this cancer type and other cancer types
Contraindicated No evidence available
Mutations
Gene Amino Acid
Change Geneotype Class cation
Current FDA Information
NCCN Guideline
Number of therapies with clinical trials in this
therapies
2 15
1 1
3
KRAS p.Ala146Thr c.436G>A Gain of F unction
KIT p.Met541Leu c.1612A>C Gain of F unction
MET p.Asn375Ser c.1124A>G Gain of F unction
Copy Number Variations
Gene Type Class cation Current FDA Information
NCCN Guideline
Number of therapies with clinical trials in this therapies
ER
Other mutations, copy number variations, or fusions that were detected but not classi ed by the Oncofocus Knowledgebase as a genetic driver of cancer are not listed in the results section of this report. All other genes listed in the Test Description that do not appear in the results section either did not have a detected variant or the variant is not classi ed as a genetic driver for cancer.
Fusion n s
3 15 2
RET Fusion 1
Class cation Current FDA Information
NCCN Guideline
Number of therapies with clinical trials in this therapies
1
Oncologica UK Ltd, Suite 15-16, The Science Village, Chesterford Research Park, Cambridge, CB10 1XL
www.oncologica.com - Tel: +44 (0)1223 785327 - [email protected]
Oncofocus Patient Test Report
Read the Full Report onhttp://oncologica.com/report
14 15
PROFILING FLOW EXAMPLE
LONGITUDINAL DYNAMIC MONITORINGOF PATIENTS RECEIVING TARGETED THERAPIES
Candidate treatment:erlotinib,gefitinib,
afatinib,dacomitinibneratinib
Candidate treatment:AZD-9291
Routine histologicalsamples
Liquid biopsye.g.ctDNA, CTCs
Initial profiling e.g EGFR L858Rmutation
Primary diagnosis
Relapse
Secondary profiling,e.g. EGFR T790Mresistance mutation
21 4 5 6 73
SERVICE FLOW
TURNAROUND TIME:10 DAYS
Prepare template
Template enrichment
Run sequence
Data Analysis
Report generation Return of hardcopy and sample
Secure electronictransfer of report
DNA+RNA extraction
Construct Library
Sample receiptFFPE block, curlor liquid biopsy
ACTIONABLE DIAGNOSIS
DRUG RESPONSIVENESS ANALYSIS
CLINICAL TRIALS INFORMATION
ONCOFOCUS PATIENT TEST REPORT
Alteration Tumour type Example treatment(s)
ALK fusion NSCLC ceritinib, crizotinib
AKT1 mutation Multi cancer MK-2206, MSC-2363318A
*BAP1 mutation Melanoma vorinostat
BRAF mutation Melanoma dabrafenib, trametinib, vemurafenib
BRAF mutation NSCLC dabrafenib, vemurafenib
BRCA1 mutation, deletion Multi cancer rucaparib, veliparib
BRCA2 mutation, deletion Multi cancer rucaparib, veliparib
CCND1 amplification Multi cancer palbociclib
CDK4 amplification, mutation Melanoma, NSCLC palbociclib
CDK6 amplification NSCLC palbociclib
*CDKN2A mutation Multi cancer crizotinib + dasatinib, palbociclib
DDR2 mutation Multi cancer crizotinib + dasatinib
EGFR mutation NSCLC afatinib, erlotinib
ERBB2 amplification Breast cancer pertuzumab, trastuzumab
ERBB2 amplification Gastric cancer trastuzumab
ERBB2 amplification NSCLC afatinib
ERBB3 mutation Multi cancer neratinib
FGFR1-4 mutation, amplification, fusion
Multi cancer BGJ-398, JNJ-42756493
GNA11 mutation Melanoma vorinostat
GNAQ mutation Melanoma vorinostat
HRAS mutation Multi cancer binimetinib + panitumumab, BVD-523
Approved - FDA labels Investigational - TrialsApproved - NCCN
EXAMPLES OF GENETIC VARIANTSAND TARGETED TREATMENTS
*available soon
IDH1 mutation Multi cancer AG-120
KIT amplification Melanoma dasatinib
KIT mutation Melanoma imatinib mesylate
KIT mutation GIST imatinib, sunitinib, regorafenib
KRAS mutation Colorectal cancer cetuximab, panitumumab contraindicated
KRAS mutation Multi cancer various MEKi combinations
MET amplification NSCLC crizotinib
MET mutation Multi cancer AMG-337, crizotinib, INCB-028060
MTOR mutation Multi cancer MSC-23633188A
MYCN amplification Multi cancer GSK-525762
NRAS mutation Colorectal cancer cetuzimab, panitumumab contraindicated
NRAS mutation Multi cancer various MEKi combinations
PDGFRA amplification Glioblastoma nilotinib, sorafenib
PDGFRA mutation GIST dasatinib
PIK3CA mutation Multi cancer various PI3K pathway combinations
PPARG fusion Thyroid cancer pioglitazone
*PTCH1 mutation Multi cancer vismodegib
PTEN deletion, mutation Multi cancer various PI3K pathway combinations
RET fusion NSCLC cabozantinib
RET mutation NSCLC, Thyroid cancer ponatinib, sunitinib
ROS1 fusion NSCLC crizotinib
SMO mutation Multi cancer vismodegib
STK11 mutation Multi cancer MSC-2363318A
TP53 mutation Multi cancer MK-1775, MK-8242
*TSC1,2 m utation Multi cancer MSC-2363318A
Alteration Tumour type Example treatment(s)
18 19
Oncofocus was developed as part of the US NCI-MATCH (Molecular Analysis for Therapy Choice) program for precision oncology involving 2400 NCI-affiliated hospitals, >700,000 patients samples, 120 phase 3 and 215 early phase trials.
The Oncofocus test utilises state of the art semiconductor technology to rapidly sequence DNA/RNA extracted from routine FFPE surgical biopsy material. The assay is designed to detect thousands of genetic alterations including SNPs, indels, CNVs and fusions across 52 of the major cancer driver genes linked to solid tumours. The data generated by the Oncofocus test is analysed using Oncologica’s bionformatics platforms linked to the world’s largest curated compendium of cancer genetic information, enabling genetic alterations/variants to be linked to over 280 targeted therapies. Targeted therapies include all classes: -FDA approved therapies, -national comprehensive cancer network (NCCN) guideline referenced therapies and -therapies entered into US, EU and Japanese phase I, II and III clinical trials.
ONCOLOGICA TEST MENU FOR PERSONALISED ONCOLOGY
ONCOFOCUS PANEL52 GENE LIST SUMMARY
Additional tests for targeted therapies available.Please visit www.oncologica.com or contact us for more information
CNV HOTSPOT + CNV + FUSIONFUSION HOTSPOT HOTSPOT + FUSION CNV + FUSIONHOTSPOT + CNV
AKT1ALK AR BRAF CDK4CTNNB1 DDR2 EGFR ERBB2 ERBB3 ERBB4 ESR1 FGFR2
FGFR3 GNA11 GNAQ HRASIDH1IDH2JAK1JAK2JAK3 KITKRAS MAP2K1 MAP2K2
METMTOR NRASPDGFRA PIK3CA RAF1RETROS1SMO
HOTSPOTGENES
ALK AR BRAF CCND1 CDK4 CDK6 EGFR ERBB2 FGFR1 FGFR2 FGFR3 FGFR4 KIT
KRAS MET MYC MYCN PDGFRA PIK3CA
COPY NUMBER VARIANTS
35 19 23
ABL1AKT3ALKAXLBRAFEGFRERBB2ERGETV1ETV4ETV5FGFR1FGFR2
FGFR3METNTRK1NTRK2NTRK3PDGFRAPPARGRAF1RETROS1
FUSION DRIVERS
Oncofocus Test Comprehensive NGS targeted panel for precision therapy
52to
Genes relevantto solid tumors
gene alterations
aligneddetection of thousands of
variants
targeted therapies andmany more
undergoing clinical trials
over 270
20 21
Professor Gareth Williams and Dr Marco Loddo are Co-founders and Directors of Oncologica and have in-depth knowledge and expertise in diagnostic oncopathology, translational biology, biomarker discovery and drug development.
Kitty Williams is the Senior Commercial Manager and is responsible for providing advice and implementation on commercial and corporate matters
Philippa Jones is the Senior Operations Manager and directs the tissue based diagnostic services of the company.
Katherine Marquis is the Senior Biomedical Scientist who directs the precision oncology services for targeted therapies
Keeda-Marie Snelson is the Lead Clinical Scientist with extensive expertise in the analysis of cancer genetic variants of clinical prognostic and predictive significance.
Rebecca Cadman is the Business Development Manager and is responsible for exploring new market opportunities and providing comprehensive support for existing clients.
MANAGEMENT TEAM
Read more about our team by visitng www.oncologica.com/about-us/our-team/
Suite 15-16, The Science Village, Chesterford Research Park, Cambridge, CB10 1XL
www.oncologica.com
TELEPHONE
+44 (0)1223 785327
22
Suite 15-16, The Science Village, Chesterford Research Park Cambridge, CB10 1XL
ww
w.dbs.agency
V150915193433U
K
www.oncologica.com